The observed decline in the AAMRs of prostate, bladder, and kidney cancer may be attributable to the increased uptake of screening methods, such as serum prostate-specific antigen (PSA) levels and diagnostic imaging, and advances in the treatment of genitourinary cancers that have prolonged overall survival. Here, KLK3 is linked to urogenital neoplasm.